U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07288515) titled 'Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus' on Nov. 17.
Brief Summary: to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
Study Start Date: Dec. 31
Study Type: OBSERVATIONAL
Condition:
Chronic Lymphocytic Leukemia
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Published by HT Digital Content Services with permission from Health Daily Digest....